There are clinical trials being performed with Crizotinib in neuroblastoma given the suspected role ALK mutations play in the malignancy of this disease.12 Of interest to our case report, recent work was published highlighting ALK mutations being over expressed in angiomatoid fibrous histiocytoma (AFH) raising questions of therapeutic potential. This evidence concerns the gene ALK and neuroblastoma.